Emd 128130    (DrugBank: -)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病3
156レット症候群1

6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 2,123 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-001593-10-IT02/12/200403/01/2005A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1)A double-blind, placebo-controlled, multicenter, multinational Phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d. in patients with Parkinson's disease suffering from treatment-associated dyskinesia (PADDY 1) Treatment-Associated Dyskinesia in Parkinson's DiseaseProduct Name: Sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: Sarizotan hydrochloride
MERCK S.P.A.NULLNot RecruitingFemale: yes
Male: yes
Phase 3United Kingdom;Italy
2EUCTR2004-001594-25-ES24/11/200402/11/2004A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from treatment-associated dyskinesia. - PADDY-2A double-blind, placebo controlled, multicenter, multinational, phase III study to evaluate the safety and efficacy of Sarizotan HCl 1 mg b.i.d in patients with Parkinson' s disease suffering from treatment-associated dyskinesia. - PADDY-2 Treatment-Associated Dyskinesia in Parkinson's DiseaseProduct Name: Sarizotan
Product Code: EMD 128130
INN or Proposed INN: Sarizotan Hydrochloride
MERCK KGaANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
600Phase 3Finland;Spain
3NCT00009048January 200123/1/2001EMD 128130 for the Treatment of Parkinson's DiseaseEffect of Serotoninergic Treatment in Parkinson's DiseaseParkinson's DiseaseDrug: EMD 128130;Drug: IV LevodopaNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth30Phase 2United States

156. レット症候群 [臨床試験数:36,薬物数:49(DrugBank:19),標的遺伝子数:77,標的パスウェイ数:112
Searched query = "Rett syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 36 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-004448-20-GB28/11/201623/09/2016Sarizotan: Treatment in patients with Rett Syndrome with Respiratory Symptoms.A Randomized, Double-Blind, Placebo-Controlled, Six-Month Study to Evaluate the Efficacy, Safety and Tolerability of Sarizotan in Patients with Rett Syndrome with Respiratory Symptoms Rett syndrome
MedDRA version: 20.0Level: LLTClassification code 10039000Term: Rett's disorderSystem Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: sarizotan hydrochloride
Other descriptive name: SARIZOTAN HYDROCHLORIDE
Product Name: sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: sarizotan hydrochloride
Other descriptive name: SARIZOTAN HYDROCHLORIDE
Product Name: sarizotan hydrochloride
Product Code: EMD 128130
INN or Proposed INN: sarizotan hydrochloride
Other descriptive name: SARIZOTAN HYDROCHLORIDE
Newron Pharmaceuticals S.p.A.NULLNot RecruitingFemale: yes
Male: yes
129Phase 2United States;Australia;Italy;United Kingdom;India